KR102873219B1 - Egfr 저해제 - Google Patents

Egfr 저해제

Info

Publication number
KR102873219B1
KR102873219B1 KR1020237001973A KR20237001973A KR102873219B1 KR 102873219 B1 KR102873219 B1 KR 102873219B1 KR 1020237001973 A KR1020237001973 A KR 1020237001973A KR 20237001973 A KR20237001973 A KR 20237001973A KR 102873219 B1 KR102873219 B1 KR 102873219B1
Authority
KR
South Korea
Prior art keywords
group
compound
leu
egfr
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237001973A
Other languages
English (en)
Korean (ko)
Other versions
KR20230026451A (ko
Inventor
게이 오구치
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20230026451A publication Critical patent/KR20230026451A/ko
Application granted granted Critical
Publication of KR102873219B1 publication Critical patent/KR102873219B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020237001973A 2020-07-15 2021-07-14 Egfr 저해제 Active KR102873219B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-121525 2020-07-15
JP2020121525 2020-07-15
PCT/JP2021/026461 WO2022014639A1 (ja) 2020-07-15 2021-07-14 Ｅｇｆｒ阻害剤

Publications (2)

Publication Number Publication Date
KR20230026451A KR20230026451A (ko) 2023-02-24
KR102873219B1 true KR102873219B1 (ko) 2025-10-17

Family

ID=79554696

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001973A Active KR102873219B1 (ko) 2020-07-15 2021-07-14 Egfr 저해제

Country Status (12)

Country Link
US (1) US20230285397A1 (https=)
EP (1) EP4197538A4 (https=)
JP (1) JP7495983B2 (https=)
KR (1) KR102873219B1 (https=)
CN (1) CN116368136B (https=)
AU (1) AU2021309779B2 (https=)
BR (1) BR112023000770A2 (https=)
CA (1) CA3189460A1 (https=)
MX (1) MX2023000693A (https=)
PH (1) PH12023550119A1 (https=)
TW (1) TW202216152A (https=)
WO (1) WO2022014639A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4183395A4 (en) * 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
BR112023000765A2 (pt) * 2020-07-15 2023-02-07 Taiho Pharmaceutical Co Ltd Cristal de composto de pirimidina
EP4351737A4 (en) * 2021-05-24 2025-05-14 Taiho Pharmaceutical Co., Ltd. Treatment methods for subjects with cancer having an aberration in egfr and/or her2
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065898A2 (en) 2008-12-05 2010-06-10 Principia Biopharma Inc. Egfr kinase knockdown via electrophilically enhanced inhibitors
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
WO2017038838A1 (ja) 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩
WO2020145374A1 (ja) 2019-01-11 2020-07-16 大鵬薬品工業株式会社 ピリミジン化合物又はその塩

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034885B2 (en) * 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
ES2775751T3 (es) * 2016-02-23 2020-07-28 Taiho Pharmaceutical Co Ltd Nuevo compuesto de pirimidina condensada o sal del mismo

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065898A2 (en) 2008-12-05 2010-06-10 Principia Biopharma Inc. Egfr kinase knockdown via electrophilically enhanced inhibitors
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
WO2017038838A1 (ja) 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩
WO2020145374A1 (ja) 2019-01-11 2020-07-16 大鵬薬品工業株式会社 ピリミジン化合物又はその塩
KR102640463B1 (ko) * 2019-01-11 2024-02-23 다이호야쿠힌고교 가부시키가이샤 피리미딘 화합물 또는 그 염

Also Published As

Publication number Publication date
JPWO2022014639A1 (https=) 2022-01-20
BR112023000770A2 (pt) 2023-02-07
EP4197538A1 (en) 2023-06-21
AU2021309779A1 (en) 2023-02-23
JP7495983B2 (ja) 2024-06-05
WO2022014639A1 (ja) 2022-01-20
US20230285397A1 (en) 2023-09-14
MX2023000693A (es) 2023-02-13
KR20230026451A (ko) 2023-02-24
CA3189460A1 (en) 2022-01-20
AU2021309779B2 (en) 2024-06-27
CN116368136A (zh) 2023-06-30
EP4197538A4 (en) 2024-08-07
TW202216152A (zh) 2022-05-01
PH12023550119A1 (en) 2024-06-24
CN116368136B (zh) 2025-09-05

Similar Documents

Publication Publication Date Title
KR102873219B1 (ko) Egfr 저해제
KR102640463B1 (ko) 피리미딘 화합물 또는 그 염
JP7373664B2 (ja) 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
TWI905228B (zh) 嘧啶化合物之結晶
RU2817044C1 (ru) Ингибитор egfr
RU2787992C1 (ru) Пиримидиновое соединение или его соль
HK40090490B (zh) Egfr抑制剂
HK40090490A (zh) Egfr抑制剂
HK40056369A (en) Pyrimidine compound or salt thereof
HK40056369B (zh) 嘧啶化合物或其盐
BR112021013460B1 (pt) Composto pirimidina, composição farmacêutica e agente antitumoral que compreendem o mesmo e usos do dito composto para o tratamento de tumor
BR122024008319A2 (pt) Composto pirimidina, composição farmacêutica e agente antitumoral que compreendem o mesmo e usos do dito composto para o tratamento de tumor

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)